Damora starts Phase 1/1b trial of DMR-001 for blood disorders

August 5, 2026 8:01 AM

Damora Therapeutics (NASDAQ: DMRA) announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial evaluating DMR-001, an investigational monoclonal ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found